GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clever Leaves Holdings Inc (OTCPK:CLVV) » Definitions » EBIT

Clever Leaves Holdings (Clever Leaves Holdings) EBIT : $-19.65 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Clever Leaves Holdings EBIT?

Clever Leaves Holdings's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-5.02 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-19.65 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Clever Leaves Holdings's annualized ROC % for the quarter that ended in Dec. 2023 was -87.54%. Clever Leaves Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -124.58%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Clever Leaves Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3,777.88%.


Clever Leaves Holdings EBIT Historical Data

The historical data trend for Clever Leaves Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clever Leaves Holdings EBIT Chart

Clever Leaves Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
-43.20 -21.44 -37.86 -41.42 -19.68

Clever Leaves Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.37 -4.13 -3.23 -7.27 -5.02

Competitive Comparison of Clever Leaves Holdings's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Clever Leaves Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clever Leaves Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clever Leaves Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Clever Leaves Holdings's EV-to-EBIT falls into.



Clever Leaves Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clever Leaves Holdings  (OTCPK:CLVV) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Clever Leaves Holdings's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-19.648 * ( 1 - -1.35% )/( (25.992 + 19.505)/ 2 )
=-19.913248/22.7485
=-87.54 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Clever Leaves Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-20.092/( ( (13.572 + max(4.524, 0)) + (13.15 + max(1.01, 0)) )/ 2 )
=-20.092/( ( 18.096 + 14.16 )/ 2 )
=-20.092/16.128
=-124.58 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.746 + 7.709 + 0.927) - (5.313 + 0.437 + 0.108)
=4.524

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.907 + 4.483 + 0.547) - (4.907 + 0.02 + 0)
=1.01

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Clever Leaves Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-19.645/0.520
=-3,777.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clever Leaves Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Clever Leaves Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Clever Leaves Holdings (Clever Leaves Holdings) Business Description

Traded in Other Exchanges
N/A
Address
19-B Parque Industrial Tibitoc, Tocancipá, Cundinamarca, Bodega, Colombia, BC, CAN
Clever Leaves Holdings Inc is a producer of pharmaceutical and consumer cannabis brands. The company operates and has investments in Canada, Colombia, Germany, Portugal, and the United States. The company operates in two reportable segments, 1. The Cannabinoid operating segment: is comprised of the Company's cultivation, extraction, and commercialization of cannabinoid products. 2. Non-Cannabinoid operating segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements.
Executives
Andres Fajardo director, officer: President CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Julian Wilches officer: Chief Regulatory Officer CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Hague Henry R Iii officer: Chief Financial Officer 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Gary M Julien director ONE LANDMARK SQUARE, 22ND FLOOR, STAMFORD CT 06901
William Muecke director C/O CLEVER LEAVES HOLDINGS, 6501 CONGRESS AVE, SUITE 240, BOCA RATON FL 33487
David Kastin officer: General Counsel C/O VITAMIN SHOPPE, INC., SECAUCUS NJ 07094
Kyle Detwiler director, officer: Chief Executive Officer CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
George J Schultze 10 percent owner C/O SCHULTZE ASSET MANAGEMENT, LLC, 3000 WESTCHESTER AVENUE, PURCHASE NY 10577
Elisabeth H Demarse director CREDITCARDS.COM, 13809 RESEARCH BOULEVARD, SUITE 906, AUSTIN TX 78750
Etienne H. Deffarges director ACCRETIVE HEALTH, INC., 401 NORTH MICHIGAN AVENUE, SUITE 2700, CHICAGO IL 60611
Schultze Special Purpose Acquisition Sponsor, Llc 10 percent owner 800 WESTCHESTER AVENUE, SUITE 632, RYE BROOK NY 10573
Amit Pandey officer: Interim CFO CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017